. 2023 Nov 20;44(1):23–46. doi: 10.1002/cac2.12505

TABLE 4.

Results of phase III trials of neoadjuvant immunotherapy for resectable LA‐NSCLC.

Trial	No. of patients (stage)	Regimen	MPR rate	pCR rate	Median EFS (months) (HR; 95% CI)
CheckMate 816 [59, 60] (NCT02998528)	228 (IIIA)	Nivolumab + CT vs. CT × 3cycles → S → CT ± RT	40.7% vs. 9.6%	23% vs. 0.9%	31.6 vs.15.7 (HR = 0.54; 95% CI = 0.37‐0.80)

Trial

No. of patients (stage)

Regimen

MPR rate

pCR rate

Median EFS (months) (HR; 95% CI)

CheckMate 816 [59, 60]

(NCT02998528)

228 (IIIA)

Nivolumab + CT vs. CT × 3cycles → S → CT ± RT

40.7% vs. 9.6%

23% vs. 0.9%

31.6 vs.15.7 (HR = 0.54; 95% CI = 0.37‐0.80)

Abbreviations: LA‐NSCLC, locally advanced‐non‐small cell lung cancer; CT, chemotherapy; S, surgery; RT, radiotherapy; MPR, major pathological response; pCR, pathological complete response; EFS, event‐free survival; HR, hazard ratio; CI, confidence interval.